Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).
1 finding from 1 review
FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma not well controlled on ICS
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Hospital admissions · Adults with acute asthma
Combination inhaled therapy probably leads to lower hospitalisation compared with SABA alone (moderate certainty).
1 finding from 1 review
Total adverse events · Adults with acute asthma
Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).
1 finding from 1 review
FEV1 · Adults with acute asthma
1 finding from 1 review
Percent change FEV₁(%) · Adults with acute asthma
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · Adults with acute asthma
1 finding from 1 review
Change in PEF · Adults with acute asthma
1 finding from 1 review
Relapse · Adults with acute asthma
Combination inhaled therapy probably leads to lower relapse rates compared with SABA alone (moderate certainty).
1 finding from 1 review
Inhaled steroid dose · mild asthma
1 finding from 1 review
Inhaled steroid dose · mild asthma
1 finding from 1 review
Total systemic steroid dose · mild asthma
1 finding from 1 review
Adverse events · mild asthma
As‐required FABA/ICS inhalers showed no clear difference in adverse events compared with regular inhaled steroid (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · mild asthma
As‐required FABA/ICS inhalers showed no clear difference in exacerbations requiring systemic steroid compared with regular inhaled steroid (low certainty).
1 finding from 1 review
Hospital admission, ED and urgent care visits · mild asthma
As‐required FABA/ICS inhalers may leads to lower hospital admission, ED and urgent care visits compared with regular inhaled steroid (low certainty).
1 finding from 1 review
Asthma control · mild asthma
1 finding from 1 review
Outcomes (weighted · stable COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found